The federal government’s anti-drug efforts are inefficient and ineffective, according to a just released report issued by the Congressional watchdog agency, the US Government Accountability Office (GAO).
As if we didn’t know.
The GAO report assessed whether the Obama administration’s anti-drug strategies, as articulated by the White House Office of National Drug Control Policy (the ONDCP aka the Drug Czar’s office) in its 2010 National Drug Control Strategy report, have yet to achieve its stated goals.
The answer? They haven’t.
States the GAO:
“The public health, social, and economic consequences of illicit drug use, coupled with the constrained fiscal environment of recent years, highlight the need to ensure that federal programs efficiently and effectively use their resources to address this problem. ONDCP has developed a 5-year Strategy to reduce illicit drug use and its consequences, but our analysis shows lack of progress toward achieving four of the Strategy’s five goals for which primary data are available.”
In particular, the GAO criticized the administration for failing to adequately address rising levels of youth marijuana consumption. The GAO also rebuffed the ONDCP’s allegation that increased rates adolescent marijuana use are a result of the passage of statewide laws decriminalizing the plant or allowing for its therapeutic use.
“Other factors, including state laws and changing attitudes and social norms regarding drugs, may also affect drug use. We examined studies on three of these other factors, which we refer to as societal factors, which may affect youth marijuana use. … The studies that assessed the effect of medical marijuana laws that met our review criteria found mixed results on effects of the laws on youth marijuana use. … [S]tudies that assessed the effect of marijuana decriminalization that met our review criteria found little to no effect of the laws on youth marijuana use.”
You can read the full GAO report here.
“Former public servants, from DEA chiefs to cops, are using their clout to lobby for drug policies that enrich themselves.”
That’s the sub-headline on today’s exceptional feature story on TheFix.com highlighting the revolving door of moneyed interests in perpetuating the war on cannabis.
Author Kevin Gray, whose work has appeared in numerous outlets including The Washington Post, articulately summarizes the role of former drug czars, cops, federal bureaucrats, and others who lobby the keep the drug war machine moving forward — and, as a result, line their own pockets.
“The time-honored revolving door between government and business swings fast and often. It can be straightforward, like the appointment of banking behemoth Goldman Sachs’ alumni as economic policymakers by recent presidential administrations. But when it comes to the drug war, the family tree is more like a thicket of interests among law enforcement, federal and state prisons, pharmaceutical giants, drug testers and drug treatment programs—all with an economic stake in keeping pot illegal.”
The whole story is really a must read. Here is the link to the full text.
Members of Congress reintroduced legislation this week to protect state-authorized medical marijuana patients from federal prosecution.
House Bill 689, the States’ Medical Marijuana Patient Protection Act, would ensure that medical cannabis patients in states that have approved its use will no longer have to fear arrest or prosecution from federal law enforcement agencies. It states, “No provision of the Controlled Substances Act shall prohibit or otherwise restrict in a State in which marijuana may be prescribed or recommended by a physician for medical use under applicable State law.”
The measure also calls for the federal government to reclassify cannabis so that it is no longer categorized as a Schedule I prohibited substance with no accepted medical use and a high potential for abuse. It states: “Not later than one year after the date of enactment of this Act, the Administrator of the Drug Enforcement Administration shall, based upon the recommendation under paragraph (1), issue a notice of proposed rulemaking for the rescheduling of marijuana within the Controlled Substances Act, which shall include a recommendation to list marijuana as other than a Schedule I or Schedule II.”
In January, a three-judge panel for the US Court of Appeals for the District of Columbia denied petitioners request to overturn the Obama administration’s July 2011 rejection of an administrative petition that sought to initiate hearings regarding the reclassification of marijuana under federal law.
Separate federal legislation, House Bill 710: The Truth in Trials Act, which provides an affirmative defense in federal court for defendants whose actions were in compliance with the medical marijuana laws of their state was also reintroduced this week in the US House of Representatives.
Those who wish to contact their member of Congress in support of these federal measures can do so by clicking here.
Members of Congress will introduce historic legislation today to permit for the regulated production and retail sales of cannabis to adults in states that have legalized its consumption.
Representative Jared Polis, (D-CO) is sponsoring legislation that seeks to regulate marijuana in a manner similar to alcohol.
Separate legislation to be introduced by Rep. Earl Bluemenauer (D-OR) seeks to establish a federal tax structure for retail cannabis production and sales.
Both Representatives, along with drug policy reform advocates, will discuss these measures at a teleconference this afternoon.
“When residents of Colorado and Washington voted to end their state’s prohibition on marijuana last November, it was a watershed moment for our nation’s move towards sane marijuana laws,” said NORML Communications Director Erik Altieri, who will be speaking at today’s teleconference. “But there remains a lingering conflict between state and federal law. These historic measures seek to resolve this conflict and empower states to dictate their own marijuana policies, without fear of federal incursion. NORML would like to thank the Congressmen for taking this brave step forward and encourages their colleagues in Congress to join them in calling for sensible marijuana law reform.”
Both Representatives have also released a report today outlining the need for federal marijuana law reform, titled “A Path Forward: Rethinking Federal Marijuana Policy.” The report states that “it is time for Congress to allow states and voters to decide how they want to treat marijuana. The current system is broken. It wastes resources and destroys individual lives, in turn damaging families and entire communities. It is past time to take action and stop this tragic waste in the future.”
Members of Congress will also call for the establishment of a Congressional Working Group on Sensible Drug Policy.
You can read the full text of that paper here.
Please check back the NORML website later this afternoon for further details regarding today’s press conference.
In a 28-page decision, the US Court of Appeals for the District of Columbia Circuit has denied petitioners request to overturn the July 2011 denial by the Drug Enforcement Administration to initiate proceedings to reschedule marijuana under federal law.
In October 2002, the Coalition to Reschedule Cannabis, a coalition of reform organizations including NORML, ASA, Patients Out of Time and High Times, among others, petitioned the DEA to reschedule marijuana as a Schedule III, IV, or V drug. Following years of administrative delay, on July 8, 2011, the DEA denied the petition, finding that “[t]here is no currently accepted medical use for marijuana in the United States,” and that “[t]he limited existing clinical evidence is not adequate to warrant rescheduling of marijuana under the CSA.”
Petitioners then sought review in the federal Court of Appeals, alleging the decision by the DEA was arbitrary and capricious when it concluded that marijuana lacks a “currently accepted medical use” and has a “high potential for abuse.” They ask this court to remand the case to the DEA for reconsideration of its decision.
Written by Senior Circuit Judge Edwards, the decision ruled “On the record before us, we hold that the DEA’s denial of the rescheduling petition survives review under the deferential arbitrary and capricious standard. The petition asks the DEA to reclassify marijuana as a Schedule III, IV, or V drug, which, under the terms of the CSA, requires a ‘currently accepted medical use.’ The DEA’s regulations, which we approved in Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131 (D.C. Cir. 1994), define ‘currently accepted medical use’ to require, inter alia, ‘adequate and well-controlled studies proving efficacy.’ Id. at1135. We defer to the agency’s interpretation of these regulations and find that substantial evidence supports its determination that such studies do not exist.
“In its scientific and medical evaluation,” the court held, “DHHS concluded that marijuana lacks a currently accepted medical use in the United States. In reaching this conclusion, DHHS applied the DEA’s established five-prong test, which requires a known and reproducible drug chemistry, adequate safety studies, adequate and well-controlled studies demonstrating efficacy, acceptance of the drug by qualified experts, and widely available scientific evidence.”
“We will not disturb the decision of an agency that has ‘examine[d] the relevant data and articulate[d] a satisfactory explanation for its action including a rational connection between the facts found and the choice made.’”
In this case, we need only look at one factor, the existence of “adequate and well-controlled studies proving efficacy,” to resolve Petitioners’ claim.
At bottom, the parties’ dispute in this case turns on the agency’s interpretation of its own regulations. Petitioners construe “adequate and well-controlled studies” to mean peer-reviewed, published studies suggesting marijuana’s medical efficacy. The DEA, in contrast, interprets that factor to require something more scientifically rigorous.
In making this assessment, we must “remind ourselves that our role in the Congressional scheme is not to give an independent judgment of our own, but rather to determine whether the expert agency entrusted with regulatory responsibility has taken an irrational or arbitrary view of the evidence assembled before it.
The DEA’s construction of its regulation is eminently reasonable. Therefore, we are obliged to defer to the agency’s interpretation of “adequate and well-controlled studies.” Judged against the DEA’s standard, we find nothing in the record that could move us to conclude that the agency failed to prove by substantial evidence that such studies confirming marijuana’s medical efficacy do not exist.”
Petitioners are considering their legal options at this time.